NASDAQ:AQXP - Aquinox Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.00 -0.05 (-1.64 %)
(As of 08/21/2018 04:00 PM ET)
Previous Close$3.05
Today's Range$2.98 - $3.05
52-Week Range$1.96 - $16.90
Volume129,800 shs
Average Volume413,366 shs
Market Capitalization$70.85 million
P/E Ratio-1.41
Dividend YieldN/A
Beta-13.81
Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive AQXP News and Ratings via Email

Sign-up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AQXP
CUSIPN/A
Phone604-629-9223

Debt

Debt-to-Equity RatioN/A
Current Ratio7.74
Quick Ratio7.74

Price-To-Earnings

Trailing P/E Ratio-1.41
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.21 per share
Price / Book0.71

Profitability

EPS (Most Recent Fiscal Year)($2.14)
Net Income$-50,180,000.00
Net MarginsN/A
Return on Equity-40.88%
Return on Assets-36.86%

Miscellaneous

Employees51
Outstanding Shares23,540,000
Market Cap$70.85 million

Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its earnings results on Wednesday, August, 8th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.71. The company earned $25 million during the quarter. View Aquinox Pharmaceuticals' Earnings History.

When is Aquinox Pharmaceuticals' next earnings date?

Aquinox Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Aquinox Pharmaceuticals.

What price target have analysts set for AQXP?

4 Wall Street analysts have issued 12-month price objectives for Aquinox Pharmaceuticals' shares. Their predictions range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' stock price to reach $25.25 in the next year. This suggests a possible upside of 741.7% from the stock's current price. View Analyst Price Targets for Aquinox Pharmaceuticals.

What is the consensus analysts' recommendation for Aquinox Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquinox Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aquinox Pharmaceuticals.

What are Wall Street analysts saying about Aquinox Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (7/2/2018)
  • 2. Cantor Fitzgerald analysts commented, ": We are downgrading our opinion of AQXP stock from and we are lowering our PT from $28 to $2. LEADERSHIP-301 trial and the decision to discontinue all rosiptor development leaves the company with little value other than cash, in our opinion." (6/27/2018)
  • 3. Needham & Company LLC analysts commented, "Aquinox reported 1Q18 financial results today and we spoke with mgmt for an update. The rosiptor Phase 3 LEADERSHIP trial in Interstitial Cystitis (IC)/ Bladder Pain Syndrome (BPS) remains on track for top-line results in 3Q18, most likely in July. 12wk trial was completed in Feb 2018. We expect a positive outcome based on Phase 2 data. Mgmt plans to revisit Phase 3 design w/ FDA prior to initiation of a planned second Phase 3 trial, which we believe may begin around YE18. Patient screening in a Phase 2 trial of rosiptor in Chronic Prostatitis (CP/ CPPS) is underway. Reiterate BUY. We do not believe the stock adequately reflects value of rosiptor program in BPS/IC." (5/8/2018)
  • 4. Canaccord Genuity analysts commented, "We recently hosted a call with Dr. J. Quentin Clemens, chief of the Division of Neurourology and Pelvic Reconstruction, urology director for female pelvic medicine and professor of urology at the University of Michigan. While Dr. Clemens has not used AQXP’s rosiptor (AQX-1125), his discussion of IC/BPS provided us with more confidence in the design of the ongoing, pivotal Ph3 LEADERSHIP 301 assessing rosiptor in IC/BPS patients, which remains on track to complete enrollment in 1Q18 and for top-line data in 3Q18. We reiterate our BUY rating." (12/19/2017)

Are investors shorting Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals saw a decrease in short interest in the month of July. As of July 13th, there was short interest totalling 224,551 shares, a decrease of 70.0% from the June 29th total of 749,318 shares. Based on an average daily volume of 1,527,883 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.0% of the shares of the company are sold short. View Aquinox Pharmaceuticals' Current Options Chain.

Who are some of Aquinox Pharmaceuticals' key competitors?

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the folowing people:
  • Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 53)
  • Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 44)
  • Mr. Lloyd Mackenzie, COO & VP of R&D Operations (Age 51)
  • Ms. Shelley McCloskey, VP of HR & Admin. (Age 58)

Has Aquinox Pharmaceuticals been receiving favorable news coverage?

News articles about AQXP stock have been trending somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a coverage optimism score of 0.20 on Accern's scale. They also gave news stories about the company an impact score of 46.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Aquinox Pharmaceuticals.

Who are Aquinox Pharmaceuticals' major shareholders?

Aquinox Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Prosight Management LP (1.70%), BlackRock Inc. (1.31%), Renaissance Technologies LLC (0.24%), TD Asset Management Inc. (0.18%) and MYDA Advisors LLC (0.17%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel J Levitt, David Main and Lloyd Mackenzie. View Institutional Ownership Trends for Aquinox Pharmaceuticals.

Which major investors are selling Aquinox Pharmaceuticals stock?

AQXP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and TD Asset Management Inc.. Company insiders that have sold Aquinox Pharmaceuticals company stock in the last year include Daniel J Levitt and Lloyd Mackenzie. View Insider Buying and Selling for Aquinox Pharmaceuticals.

Which major investors are buying Aquinox Pharmaceuticals stock?

AQXP stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Renaissance Technologies LLC and MYDA Advisors LLC. View Insider Buying and Selling for Aquinox Pharmaceuticals.

How do I buy shares of Aquinox Pharmaceuticals?

Shares of AQXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquinox Pharmaceuticals' stock price today?

One share of AQXP stock can currently be purchased for approximately $3.00.

How big of a company is Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals has a market capitalization of $70.85 million. The company earns $-50,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Aquinox Pharmaceuticals employs 51 workers across the globe.

How can I contact Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]


MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel